Friday June 23rd 2017

Protective Role of Ninjurin1 KO Mice against EAE [Immunology]

Ninjurin1 is a homotypic adhesion molecule that contributes to leukocyte trafficking in experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis. However, in vivo gene deficiency animal studies have not yet been done. Here, we constructed Ninjurin1 knock-out (KO) mice and investigated the role of Ninjurin1 on leukocyte trafficking under inflammation conditions such as EAE and endotoxin-induced uveitis. Ninjurin1 KO mice attenuated EAE susceptibility by reducing leukocyte recruitment into the injury regions of the spinal cord and showed less adhesion of leukocytes on inflamed retinal vessels in endotoxin-induced uveitis mice. Moreover, the administration of a custom-made antibody (Ab26–37) targeting the Ninjurin1 binding domain ameliorated the EAE symptoms, s…

Link:  

Protective Role of Ninjurin1 KO Mice against EAE [Immunology]

Leave a Comment

More from category

MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation
MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation

/About-the-Society/News/Society-Hosts-Joint-Congressional-Briefing-on-the [Read More]

MS Society Disappointed with Senate Healthcare Bill
MS Society Disappointed with Senate Healthcare Bill

/About-the-Society/News/HealthcareBill-6-22 [Read More]

Type I interferons could have role in natural improvement of RA during pregnancy
Type I interferons could have role in natural improvement of RA during pregnancy

An international US-Danish team of scientists, led by Damini Jawaheer, Ph.D. at the UCSF Benioff Children's Hospital [Read More]

Shared decision-making essential to optimal treatment and quality of life for patients with MS
Shared decision-making essential to optimal treatment and quality of life for patients with MS

One of the cornerstones of multiple sclerosis treatment is shared decision-making between patients and their doctors [Read More]

UC consortium formed to speed up development of new drugs
UC consortium formed to speed up development of new drugs

For 12 years, UCLA researcher Dennis Slamon pursued a groundbreaking approach to treating breast cancer: Attack the [Read More]